Successful Transplantation of Kidney Allografts in Sensitized Rats After Syngeneic Hematopoietic Stem Cell Transplantation and Fludarabine

Current methods to remove donor‐specific HLA antibody (DSA) from sensitized patients remain imperfect. We tested novel approaches to desensitization using an animal model of allogeneic sensitization with skin grafts from dark agouti (DA) to Lewis rats. At the peak IgG alloantibody response we transplanted DA kidneys into nephrectomized Lewis recipients (n = 6) and all died within 10 days from antibody‐mediated rejection (AMR). Allogeneic hematopoietic stem cell transplants (HSCT) from DA donors failed to engraft after lethal or sub‐lethal irradiation. Sensitized rats given lethal irradiation plus syngeneic green fluorescent protein (GFP) + HSCT had repopulation of blood, spleen, thymus and lymph nodes by GFP+ cells. At 2 months after HSCT, serum DSA levels were reduced 60–70% and DSA (IgG) production in cultured splenocytes was also significantly decreased. However, there was only a modest improvement in graft survival from an average of 6.5 to 13.9 (n = 9) days. Adding seven daily doses of fludarabine to the preconditioning regimen resulted in long‐term survival (>90 days) in 7 out of 10 rat kidney allografts. We conclude that syngeneic HSCT performed after preconditioning with irradiation and fludarabine can reduce DSA, prevent DSA rebound and AMR, enabling successful transplantation in animals with strong antibody reactivity to the donor MHC.

[1]  A. Zachary,et al.  Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  Richard J. Jones,et al.  HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. , 2012, Blood.

[3]  R. Christopherson,et al.  Fludarabine and cladribine induce changes in surface proteins on human B-lymphoid cell lines involved with apoptosis, cell survival, and antitumor immunity. , 2012, Journal of proteome research.

[4]  D. Segev,et al.  HLA incompatible renal transplantation , 2012, Current opinion in organ transplantation.

[5]  D. Segev,et al.  Infusion of High-Dose Intravenous Immunoglobulin Fails to Lower the Strength of Human Leukocyte Antigen Antibodies in Highly Sensitized Patients , 2012, Transplantation.

[6]  A. Valujskikh,et al.  The Spleen Is the Major Source of Antidonor Antibody‐Secreting Cells in Murine Heart Allograft Recipients , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  S. Jordan,et al.  Desensitization offers hope to highly HLA-sensitized patients for a longer life expectancy after incompatible kidney transplant. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  N. Russell,et al.  Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997–2009 , 2012, British journal of haematology.

[9]  M. Abecassis,et al.  Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation , 2012, Science Translational Medicine.

[10]  Je-Jung Lee,et al.  Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma , 2011, The Korean journal of hematology.

[11]  L. Kucirka,et al.  Desensitization in HLA-incompatible kidney recipients and survival. , 2011, The New England journal of medicine.

[12]  R. Greil,et al.  Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia , 2010, Cancer Immunology, Immunotherapy.

[13]  M. Labopin,et al.  Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases , 2010, Haematologica.

[14]  V. Sharma,et al.  HLA-mismatched renal transplantation without maintenance immunosuppression. , 2008, The New England journal of medicine.

[15]  P. Chilton,et al.  Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. , 2006, Blood.

[16]  E. Fibach,et al.  Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells. , 2005, Experimental hematology.

[17]  W. Baldwin,et al.  Antibody, complement and accommodation in ABO-incompatible transplants. , 2004, Current opinion in immunology.

[18]  Zhaoli Sun,et al.  Hepatic allograft‐derived Kupffer cells regulate T cell response in rats , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  E. Wherry,et al.  Heterologous immunity provides a potent barrier to transplantation tolerance. , 2003, The Journal of clinical investigation.

[20]  D. Rubinstein,et al.  Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. , 1998, Blood.

[21]  S. Lee An improved technique of renal transplantation in the rat. , 1967, Surgery.